Azithromycin, rifabutin, and rifapentine were used to treat or prevent disseminated Mycobacterium avium complex (MAC) infections produced in rats immunosuppressed with cyclosporine. Animals with bacteremic infections were treated 1 week after intravenous inoculation with 107 CFU of MAC with azithromycin, 100 mg/kg of body weight administered subcutaneously for 5 days and then 75 mg/kg on Monday, Wednesday, and Friday, or with rifabutin or rifapentine, 20 mg/kg administered intraperitoneally on Monday through Friday. All three drugs showed efficacy after 1 and 2 months. Rifabutin cleared the organisms from tissues more rapidly than azithromycin or rifapentine. To approximate prophylaxis, treatment was started 2 weeks before intravenous inoculation with 104 organisms. MAC infections were undetectable in treated animals after 4 months, while control animals had disseminated infections. These findings support the rationale for clinical trials of treatment and prophylaxis with these agents. The cyclosporine-treated rat appears to be a useful model in which to evaluate compounds for the treatment and prophylaxis of disseminated MAC infections.
Disseminated infection with the Mycobacterium avium complex (MAC) is the most common cause of bacteremia in patients with AIDS, occurring in up to 50% of these patients (14) . Survival of MAC-and human immunodeficiency virusinfected patients is half that of those with similar stages of human immunodeficiency virus infection but who do not have disseminated MAC infections (13) . Treatment regimens with significant activity against MAC have been described, but relapses have occurred and none of the regimens have reliably eradicated the infection (9, 10, 11, 20, 25) . Thus, there is an urgent need for more effective agents and approaches to the treatment and prevention of MAC infections.
Successful treatment of established infections probably requires combination therapy with two or more effective drugs having different mechanisms of action (17) . Rifabutin and rifapentine are new rifamycin analogs which demonstrate significant in vitro activity against MAC isolates.
Studies of treatment with these agents in animal models have produced contradictory results (4, 5, 15, 16) . Azithromycin is a new azilide antibiotic which, despite its low in vitro activity against MAC, has shown promise as a treatment in animal studies (12) and early human trials (26) . This efficacy may stem from its unusual pharmacokinetic profile, which can result in high concentrations in tissues (6) .
A new model of disseminated MAC infection has recently been described in Sprague-Dawley rats immunosuppressed with cyclosporine (CsA) (2) . We evaluated the response to treatment with azithromycin, rifabutin, or rifapentine in CsA-treated rats with bacteremic MAC infections. As a model of prophylaxis, we also tested whether these drugs prevent the progression of low-grade infection.
(Results of the studies described here were presented in MATERIALS AND METHODS Drugs. Azithromycin was provided by Pfizer Central Research, Groton, Conn. Rifabutin was provided by Adria Laboratories, Dublin, Ohio. Rifapentine was provided by Merrell-Dow Pharmaceuticals, Cincinnati, Ohio. Stock solutions of azithromycin were prepared in buffered saline (pH 6.8). Rifabutin was dissolved in 95% ethanol, and rifapentine was dissolved in 100% dimethylformamide. On the morning of administration, stock solutions of azithromycin were diluted with 10% polyoxyethylated castor oil (Cremophor El; BASF, Ludwigshafen, Germany) in saline, while rifabutin and rifapentine were diluted with saline only. The final concentration of ethanol or dimethylformamide for the rifamycins was c0.5%. The dose and schedule of drug administration were selected to achieve therapeutic levels similar to those obtained in humans on the basis of the available pharmacokinetic data (6, 15 The susceptibilities of SK095 to the study drugs, shown in Table 1 , were determined by a previously described broth microdilution method (21) .
CsA-treated rats. Infectious inocula. Thawed aliquots of strain SK095 were cultured on 7H11 agar plates enriched with oleic acid, albumin, glucose, and catalase (BBL, Bethesda, Md.) and were incubated for 3 to 5 days at 37°C. Organisms were harvested in sterile water containing 0.05% Tween 80, and single-cell suspensions in saline were prepared by low-speed centrifugation. The concentration of organisms in the supernatant was determined by measuring the optical density, and dilutions were made in saline. Concentrations of viable organisms were determined by counting colonies from serial 10-fold dilutions on 7H11 agar plates.
Assays. The extent of infection was determined from serial quantitative cultures of blood, spleen, liver, and lung. Blood was obtained by cardiocentesis prior to sacrifice and was incubated in 1.5-ml VACUTAINER tubes containing saponin (Pediatric Isolater tubes; DuPont Co., Wilmington, Del.) to release intracellular organisms. Weighed specimens of organs were homogenized at a dilution of 1:10 (by weight) in 0.1% sodium deoxycholate in saline (24) . Serial dilutions of homogenates or blood were incubated on 7H11 plates at 37°C, and the colonies were counted after 7 and 14 days.
Trough levels of drugs in tissues were determined from samples that were taken when the animals were sacrificed on Monday mornings, approximately 3 days after the last dose of study drug. Concentrations of azithromycin and rifapentine in tissue were determined by bioassay with Micrococcus luteus ATCC 10240 by a standard pour plate technique (6) . The zones of inhibition produced by serial dilutions of homogenates of serum and tissue from treated animals were compared with the zones produced by measured concentrations of drug diluted in the corresponding tissue from untreated controls. Rifabutin concentrations were measured by a high-performance liquid chromatography assay modified from previously described methods (1 No bacteremia was detected in treated animals after 40 or 68 days of infection. Bacteremia was present in all control animals after 8, 40, and 68 days of infection. Mean counts ranged from 40 to 100 CFU/ml of blood, and there were no significant differences in the degree of bacteremia between groups of control animals during the course of the study.
Significantly fewer mycobacteria (P < 0.01) were recovered from the spleens and livers of treated animals after 32 days and from the lungs after 60 days when compared with the number recovered from untreated controls (Fig. 1) . Two hundred-fold and greater reductions from the baseline mycobacterial concentrations (P < 0.01) were seen in spleens and livers after 32 days of therapy in all treatment groups and in lungs in rifabutin-treated animals. Counts from the lungs of animals treated with azithromycin and rifapentine were not significantly lower than those at the start of therapy.
Rifabutin cleared MAC from all organs more rapidly than azithromycin or rifapentine did. Mean counts from the lungs and livers were below the limits of the assay after 32 days of treatment with rifabutin. After 60 days of treatment, mean counts from the spleens of animals treated with rifabutin were 100-fold less than those from the spleens of animals treated with azithromycin (P < 0.01) and 200-fold less than those from the spleens of animals treated with rifapentine (P < 0.01).
Prophylaxis. To determine the abilities of the study drugs to prevent the progression of low-grade infection, treatment was begun 1 week after starting CsA. serum and organ homogenates of three animals in each treatment group are given in Table 3 . Trough CsA levels were measured after 32 and 60 days of treatment. The combined mean serum CsA level after 32 and 60 days of treatment was 195 ± 90 ng/ml (standard deviation; range, 112 to 293 ng/ml). There were no significant differences in CsA levels within or between treatment groups over this period of time.
DISCUSSION
This is the first report of the treatment of disseminated MAC infection in CsA-treated rats. The results show that azithromycin, rifabutin, and rifapentine are effective in the treatment of bacteremic MAC infections in this model. Each of these drugs also prevented the progression of low-grade infection over 4 months.
Rifabutin was the most active of the three drugs in clearing established MAC infection from tissues. Previous reports have given conflicting accounts of the activity of rifabutin for the in vivo treatment of MAC. Furney et al. (4) have suggested that discrepancies in the activity of rifabutin observed between studies in beige mice (5) and thymectomized CD4 T-cell-deficient C57BL/6J mice (4) may be attributable to differences in the susceptibilities of the test strains used to the study drugs. Our results support this view since the strain used, SK095, was quite susceptible in vitro to rifabutin.
A similar controversy concerning the activity of rifapentine also exists (15, 16) . Our findings lend support to the view that rifapentine may have significant activity against MAC infections. Most reports of in vivo therapeutic trials have evaluated therapy after treatment for 30 days or less. Our results showed that while the activity of rifapentine was only suggestive after 30 days of treatment, it was clearly signifi- a Tissue samples from three animals in each group were assayed 60 days after the start of treatment and 3 days after the last dose was given. Levels of azithromycin in tissues were determined by a standard bioassay with M. luteus. Rifabutin levels were assayed by high-performance liquid chromatography.
cant after 60 days. Nonetheless, rifapentine was less active than rifabutin, despite good levels in tissues and the similar susceptibilities of the test strain to both of these compounds. The cause of these discrepancies is unknown, but differences in the tissue pharmacokinetics of these agents, such as intracellular compartmentalization or protein binding, could affect their bioavailability to intracellular MAC. Alternatively, intracellular organisms may have phenotypic characteristics that alter the in vivo susceptibility of a strain when compared with its in vitro phenotype.
Azithromycin has shown in vivo activity against MAC in animals and humans, despite poor in vitro susceptibilities. As with other macrolides, the MIC of azithromycin decreases as the pH increases (22) . The MIC for MAC strain SK095 was 10 times greater than the measured concentration in serum at pH 7.5 and 60 times greater than the measured concentration in serum at pH 6.5. In contrast, the concentrations of azithromycin in tissues ranged from 10 to 100 times the MICs for the organism. These data support the concept that the antimycobacterial activity of azithromycin results from the unusually high concentrations in tissues which can be obtained with this drug. The use of in vitro susceptibilities as a guide to therapy may not be useful with this class of agents or with other compounds with long half-lives in tissues. Thus, the use of animal models remains of critical importance for the evaluation of novel treatments for MAC infections.
Pharmacokinetic interactions have been reported between CsA and other rifamycin and macrolide drugs. Since rifamycins may induce increased hepatic metabolism of CsA (23), a possible explanation for the observed therapeutic effects of rifabutin and rifapentine could be recovery of immune function because of subtherapeutic CsA levels. We found no difference in Csa levels between control animals and animals treated with the study drugs. Unidentified immunoadjuvant effects also seem unlikely because no significant granulomatous response in the tissues of treated animals was seen. This is in contrast to what is seen in animals recovering from MAC infections after withdrawal of CsA, in which a vigorous granulomatous response occurs. Macrolides may also affect the in vivo concentrations of CsA (18) . The azithromycin levels obtained were within the range that would be predicted by the pharmacokinetics observed in animals not treated with CsA (6). Thus, we found no significant interaction between CsA and the study drugs.
The magnitude and urgency of the problem of MAC infection in patients with AIDS and the lack of proven therapy for established disease make consideration of prophylactic treatment strategies an attractive alternative to therapy for the acute phase of infection. The value of prophylaxis for other opportunistic infections in immunocompromised patients is well established. In the case of Mycobacterium tuberculosis, prophylaxis is actually treatment of a subclinical infection with a low bacillary burden, a situation analogous to the model of prophylaxis used in the studies described here. Recently conducted clinical trials show that rifabutin is effective for prophylaxis of MAC infections in humans (8) , as it was in the animal model described here. These results appear to validate the CsAtreated rat as a model for studies of prophylaxis of MAC infections. The encouraging results obtained with azithromycin and rifapentine suggest that these drugs may also be useful in the prophylactic treatment of MAC infections.
